Internal Medicine, Pulmonary Disease · Lemoyne, PA
NPI
1518990001
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
50 N 12th St
Lemoyne, PA, 17043
Phone (717) 234-2561
Groups this clinician bills Medicare through
Medicare paid, 2024
$86K
1,472 services
Medicare patients, 2024
595
Average age 73
Drug cost, 2024
$1.4M
631 prescriptions
Company payments, 2024
$566
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Baba H Limann was code 99232 (hospital e&m - subsequent), 357 times for 130 patients. In total Baba H Limann billed 1,472 services in 37 codes, and Medicare paid $86K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 357 | 130 | $59.81 | $21K |
| 99233 Hospital E&M - Subsequent | Facility | 185 | 101 | $89.54 | $17K |
| G0399 Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 141 | 140 | $29.44 | $4,151 |
| 95810 Sleep Study | Office | 71 | 71 | $86.95 | $6,173 |
| 95811 Sleep Study | Office | 67 | 66 | $87.39 | $5,855 |
| 99213 Office E&M - Established | Office | 64 | 54 | $62.59 | $4,006 |
| J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 53 | 29 | $0.04 | $2.08 |
| 99214 Office E&M - Established | Office | 48 | 39 | $86.67 | $4,160 |
| 99222 Hospital E&M - Initial | Facility | 43 | 43 | $97.65 | $4,199 |
| 99291 Critical Care E&M | Facility | 40 | 20 | $161.58 | $6,463 |
| 94729 Pulmonary Function Testing | Office | 39 | 39 | $40.72 | $1,588 |
| 94727 Pulmonary Function Testing | Office | 31 | 31 | $32.19 | $998 |
| 99223 Hospital E&M - Initial | Facility | 26 | 26 | $131.14 | $3,410 |
| 94060 Pulmonary Function Testing | Office | 19 | 19 | $27.65 | $525 |
| 95811 Sleep Study | Facility | 15 | 15 | $86.04 | $1,291 |
By year: 2022 $110K for 1,559 services; 2023 $113K for 1,444 services; 2024 $86K for 1,472 services.
Medicare prescription drug claims, 2024
In 2024, the drug Baba H Limann prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 46 prescriptions and refills. In total Baba H Limann wrote 631 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 46 | 76 | 14 | $47K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 43 | 59 | 19 | $1,206 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 40 | 56 | Under 11 | $26K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 33 | 55 | Under 11 | $24K |
| Spiriva Respimat Tiotropium Bromide | 31 | 43 | Under 11 | $21K |
| Tadalafil Generic | 24 | 24 | Under 11 | $54K |
| Ambrisentan Generic | 23 | 23 | Under 11 | $93K |
| Opsumit Macitentan | 23 | 23 | Under 11 | $296K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 23 | 31 | Under 11 | $1,371 |
| Prednisone Generic | 21 | 37 | 12 | $159 |
| Sodium Oxybate Generic | 20 | 20 | Under 11 | $376K |
| Ropinirole Hcl Generic | 18 | 26 | Under 11 | $82.67 |
| Symbicort Budesonide/Formoterol Fumarate | 14 | 27 | Under 11 | $4,513 |
| Ipratropium Bromide Generic | 13 | 14 | Under 11 | $354 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 13 | 19 | Under 11 | $11K |
Brand drugs: 318 claims; generic drugs: 313 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Baba H Limann $566 ($566 in general payments such as food, travel and fees) from 5 companies. The largest payer was GlaxoSmithKline, LLC. with $137.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.